Amendments to the Specification:

Please replace the heading on page 1, line 5, with the following heading:

1 1

BACKGROUND OF THE INVENTION

Please add the following <u>new</u> heading on page 6, line 3:

BRIEF SUMMARY OF THE INVENTION

Please add the following <u>new</u> heading and paragraphs on page 9, line 1:

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents the expected and observed fragment patterns for the restriction digests of Example 1a.

Figure 2 presents the observed fragment patterns for BspEl-released internal control DNA restriction digests of Example 1c.

Figure 3 presents the observed fragment patterns for the restriction digests of Example 1b.

Figure 4 presents the expected and observed TRSPA-2 hybridization patterns for pNW33 using matrix 7 (Example 2).

Figure 5 presents the expected and observed TRSPA-2 hybridization patterns for pNW33 using matrix 17 (Example 2).

DETAILED DESCRIPTION OF THE INVENTION

Please replace the paragraph on page 109, line 9, though page 110, line 35, with the following amended paragraph:

BspEI sites define the outer ends of the 140 bp and the 200 bp fragments. The full

catctg taaaag caattg ttccaggaac cagggcg tatctcttcatagc catggaatacgcctttttcagtg ttgcgatgctaatgccatggaatacgcctttttcagtg ttgcgatgctaatgccatggaatacgccatggaatacgcctttttcagtg ttgcgatgctaatgccatggaatacgcctttttcagtg ttgcgatgctaatgccatggaatacgcctttttcagtg ttgcgatgctaatgccatggaatacgcatggaatacgccatggaatacgccatggaatacgccatggaatacgccatggaatacgcatggaatacgccatggaatacgccatggaatacgccatggaatacgccatggaatacgccatggaatacgccatggaatacgcatggaatacgccatggaatacgcatggaatacgcatggaatacgcatggaatacgcatggaatacgcatggaatacgcatggaatacgcatggaatacgcatggaat

gtta caa at attccg ag cacca ag aat ggctgcgcgcttgcctggtacttgacgtcgtatttgacggggtccttgag aa ag tatttageacce agact t g t gata ta acctet g get c t gatat t get c eagat g gatat t g gatat t g gatat t get c gatat t get gatat t get c gatat t get g gatat t g gateataccagtegttgattgtetgtgtatagecagtaagacaaggaccagacateateatgcaaagaategettaagecettettgge ctttatgaggatctctctgatttttcttgcgtcgagttttccggtaagacctttcggtacttcgtccacaaacacaactcctccgcgcaactttttcgcggttgttacttgactggccacgtaatccacgatctctttttccgtcatcgtctttccgtgctccaaaacaacaacagcgggcgggtccggattaccagctgcgatcaagcttatcgataccgtcgacctcgacctgcaggcatgcaagcttggcgtaatcatggtcttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacat gt gag caa aa ag gc cag caa aa ag gc cag gaa cc gt aa aa ag gc cg cg tt gc t g c gt tt tt ccat ag gc t cc gc cc cc t gaar ag gc cag gaa ag gaa acgag cat cacaaaaat cgac gct caa g t cag a g t g g cgaa a c ccga cag gac ta taa a g a ta c cag g c g t t t c c c c t g g a a c c g a cag a caggetecetegtgegeteteetgtteegaeeetgeegettaeeggataeetgteegeettteteeettegggaagegtggegetttete aggattag cagag cgagg tat gtagg cggtg ctacagag ttcttg aagtggtgg cctaactacgg ctacactag aaggacag taggagg taggagg cagagg cagct cagtggaac gaaaact cacgtta agggatttt ggt catgagattat caaaaaggatctt cacctagat cctttta aatta aaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatc tgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctg tgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa

Appl. No. 09/914,604

Amendment dated October 17, 2003

Reply to Office action of May 21, 2003

cca agt cattet gaga at agt gat agt geg eace gag t t get ctt gee eg geg at aat ae eg gat aat ae eg geg ac aat ag each gaga agt gat af a geg gat aat ae eg gag at aat ae eg gag at aat ae eg gag af aat ae eg gag ae eg ga

gaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgt

gcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattg

tct catgageggata catattt gaatgtattt agaa aa ataa acaa ataggggt tccgcgca catttccccgaa aa agtgccacctga

cgtctaagaaaccattattatcatgacattaacctataaaaataggcgtatcacgaggccctttcgtc (SEQ ID NO: 1)

Please replace the paragraph on page 115, lines 7-13, with the following amended

paragraph:

Primers and PCR

20 µM BIO140UP

5' biotin-CGCAGCTGGTAATCCGGACGCCCGCGTCGAAGATGTT 3'

(**SEQ ID NO: 2**)

20 μM BIO200DOWN

5' biotin-CGCAGCTGGTAATCCGGACCCGCCGCCGTTGTTGTT 3'

(SEQ ID NO: 3)

Please replace the paragraph on page 119, lines 9-16, with the following amended

paragraph:

After digestion, 20 µl of digests 1-7 were mixed with 10 µl of 50 % glycerol AGE

loading dye and 4 µl of digests 1-7ic were mixed with 2 µl of 50 % glycerol AGE loading

Page 6 of 32

dye. Digests in loading dye were then electrophoresed on a 2.5 % MetaPhor™ agarose gel in 1x TBE. The gel was stained for 60 min in 500 ml of 1x TBE containing 50 μl of Vistra Green. The stained gel was finally imaged on a Fluorimager with the following settings: a 488 nm laser; a 570 DF 30 filter; a PMT setting of 700 V; 200 μm resolution; and low sensitivity.

1 4

Please replace the paragraph on page 121, line 6, though page 122, line 22, with the following amended paragraph:

HindIII and EcoRI sites define the outer ends of the 25 bp and the 40 bp fragments. The sequence of pNW35 (SEQ ID NO: 4) is shown below with the inserted region shown in bold type:

ctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattg taatctcatgaccaaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcetttttttctgegegtaatctgetgettgeaaacaaaaaaaccaccgetaccageggtggtttgtttgccggatcaagagctaccaactettttteegaaggtaactggetteageagagegeagataceaaatactgteettetagtgtageegtagttaggeeaceacttegggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcgg a caggtat ccgg taagcgg cagggt cggaacaggag ag cgcacgagggag cttccagggggaaacgcctgg tatctttataga acg egg cettttta egg tte etgg eetttt get geetttt get eac at gttettte etgeg ttatee eet gattet gegat aacegt at the experiment of the expgegeceaataegeaaaeegeeteteeegegegttggeegatteattaatgeagetggeaegaeaggttteeegaetggaaage ggg cag tgag cgcaacgcaatta at gtgag ttag ctcact cattagg caccccag gctttacactt tat gctt ccg gctcg tat gttgtgtggaattgtgageggataacaatttcacacaggaaacaget (SEQ ID NO: 4)

Please replace the paragraph on page 123, lines 3-7, with the following amended paragraph:

Primers and PCR

U-19 mer bio primer 5' bio-GTTTTCCCAGTCACGACGT 3'

(SEQ ID NO: 5)

ICPCR(F) primer 5' TCCGGACGTCTCAGGCTAATGTT 3'

(SEQ ID NO: 6)

Please replace the paragraph on page 129, line 12, through page 130, line 13, with the following amended paragraph:

Oligonucleotides

BamHI short PCR primer 5' TGTAACGACACATTGCTGGATACC 3'

(SEQ ID NO: 7)

HindIII short PCR primer 5' ATATAACTCTCGCTCCTTGATAAC 3'

(SEQ ID NO: 8)

NcoI short PCR primer 5' AGGCGTCTGAGGCTGCGGCTATGG 3'

(**SEQ ID NO: 9**)

SpeI short PCR primer 5' AACCCGTCGCGACGAGAGTCTAAG 3'

(SEQ ID NO: 10)

AfIII short PCR primer 5' GATATACGTGATATATTTTGATTG 3'

(SEQ ID NO: 11)

BamHI adaptor 5' pGATCGGTATCCAGCAATGTGTCGTTACA 3'

(SEQ ID NO: 12)

HindIII adaptor 5' pAGCTGTTATCAAGGAGCGAGAGTTATAT 3'

(SEQ ID NO: 13)

NcoI adaptor 5' pCATGCCATAGCCGCAGCCTCAGACGCCT 3'

(SEQ ID NO: 14)

SpeI adaptor 5' pCTAGCTTAGACTCTCGTCGCGACGGGTT 3'

(SEQ ID NO: 15)

AfIII adaptor 5' pTTAACAATCAAAATATATCACGTATATC 3'

(SEQ ID NO: 16)

BamHI long PCR primer 5' TGTAACGACACATTGCTGGATACCGATCC 3'

(SEQ ID NO: 17)

HindIII long PCR primer 5' ATATAACTCTCGCTCCTTGATAACAGCTT 3'

(SEQ ID NO: 18)

NcoI long PCR primer 5' AGGCGTCTGAGGCTGCGGCTATGGCATGG 3'

(SEQ ID NO: 19)

SpeI long PCR primer 5' AACCCGTCGCGACGAGAGTCTAAGCTAGT 3'

(SEQ ID NO: 20)

AfIII long PCR primer 5' GATATACGTGATATATTTTGATTGTTAAG 3'

(SEQ ID NO: 21)

Luc140down primer

5' GCGCTAGGGATCCTTACTGGGACGAAGACGAA 3'

(SEQ ID NO: 22)

Luc140up-bio primer

5' biotin-CGCAGCTGGTAATCCGGACGCCCGCGTCGAAGATGTT3'
(SEQ ID NO: 23)

Please replace the paragraph on page 138, lines 6-32, with the following amended paragraph:

Clone #1

Mutant sequence (#1M)

5'CCCGGGGGATCCTCGTTTTATTGGGCCGAGTTTTGGTCCGTAGTGCTTGGTT
AGATATGCTTAT
3'GGGCCCCCTAGGAGCAAAATAACCCGGCTCAAAACCAGGCATCACGAACC
AATCTATACGAATA

GTTCACAAAATCATCCTTGTACAGAATTC3'(SEQ ID NO: 24)
CAAGTGTTTTAGTAGGAACATGTCTTAAG5'

Control sequence (#1C)

5'CCCGGGGGATCCTCGTTTTATTGGGCCGAGTTTTGGTCCGTAGTGCATGGTT
AGATATGCTTAT
3'GGGCCCCCTAGGAGCAAAATAACCCGGCTCAAAACCAGGCATCACGTACCA
ATCTATACGAATA

GTTCACAAAATCATCCTTGTACAGAATTC3' (SEQ ID NO: 25)

CAAGTGTTTTAGTAGGAACATGTCTTAAG5'

Clone #7

Control sequence (#7C)

5'CCCGGGTGTACACAAAAGTTTACCTGAAGAACGTGGGGGGTCGTGCCTGGT CTTGCGTCACCTG 3'GGGCCCACATGTGTTTTCAAATGGACTTCTTGCACCCCCCAGCACGGACCA GAACGCAGTGGAC

GTCTCAGGAGAGGGTCCCCATGGGAATTC3'(SEQ ID NO: 26)
CAGAGTCCTCTCCCAGGGGTACCCTTAAG5'

Please replace the paragraph on page 139, lines 6-8, with the following amended paragraph:

Oligonucleotides

BIOUPST2 5' bio-CTACTGATCGGATCCCCG 3' (SEQ ID NO: 27)
BIODOWN3 5' bio-AAACGACGGCCAGTGAAT 3' (SEQ ID NO: 28)

Please replace the paragraph on page 141, lines 4-7, with the following amended paragraph:

Oligonucleotides

BIOUPST2 5' bio-CTACTGATCGGATCCCCG 3' (SEQ ID NO: 29)

DOWN3 5' bio-AAACGACGGCCAGTGAAT 3' (SEQ ID NO: 30)

Please replace the paragraph on page 145, lines 4-8, with the following amended paragraph:

Oligonucleotides

#1 probe oligo 5' GGCCGAGTTTTGGTCCGTAG 3' (SEQ ID NO: 31)

#7 probe oligo 5' GTCTTGCGTCACCTGGTCTCAG 3' (SEQ ID NO: 32)

At the end of the written description, before the claims, please delete the previously submitted "Sequence Listing" and insert the revised "Sequence Listing" attached hereto.